Significant upregulation of SAMD1 occurs in cholangiocarcinoma (CHOL), diffuse large B-cell lymphoma (DLBC), head and neck squamous cell carcinoma (HNSC), brain lower-grade glioma (LGG), liver hepatocellular carcinoma (LIHC), ovarian serous cystadenocarcinoma (OV), pancreatic adenocarcinoma (PAAD), sarcoma (SARC), and thymoma (THYM). Here, SAMD1 is linked to diffuse large B-cell lymphoma.